Detailed Information on Publication Record
2023
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
POPRACH, Alexandr, Igor KISS, Michal STANÍK, Tamara BARUSOVA, Lenka POSPISILOVA et. al.Basic information
Original name
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Authors
POPRACH, Alexandr (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution), Tamara BARUSOVA (203 Czech Republic), Lenka POSPISILOVA (203 Czech Republic), Ondrej FIALA (203 Czech Republic), Jindrich KOPECKY (203 Czech Republic), Igor RICHTER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Hana STUDENTOVA (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Miloš HOLÁNEK (203 Czech Republic, belonging to the institution), Aneta ROZSYPALOVA (203 Czech Republic), Anezka ZEMANKOVA (203 Czech Republic), Marek SVOBODA (203 Czech Republic, belonging to the institution) and Tomas BUCHLER (203 Czech Republic)
Edition
Targeted Oncology, Dordrecht, Springer, 2023, 1776-2596
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.400 in 2022
RIV identification code
RIV/00216224:14110/23:00134702
Organization unit
Faculty of Medicine
UT WoS
001104868200001
Keywords in English
Renal Cell Carcinoma; Immunotherapy
Tags
International impact, Reviewed
Změněno: 31/1/2024 12:17, Mgr. Tereza Miškechová
Abstract
V originále
Background Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. Objective The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. Methods RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. Results The median overall survival from the initiation of first-line treatment was 24.5 months versus notreached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. Conclusion In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.
Links
NU21-03-00539, research and development project |
|